

YUTIQ™ Reimbursement and Diagnosis Codes

Call EyePoint™ Assist for more information: 1-833-393-7646; Option 2

Code Type	Code	Descriptor
HCPSC	J3490	Unclassified Drugs
NDC	71879-136-01	YUTIQ (fluocinolone acetonide intravitreal implant) 0.18 mg

INDICATIONS AND USAGE

YUTIQ™ (fluocinolone acetonide intravitreal implant) 0.18 mg is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.

ICD-10 Codes for Non-infectious (NI) Intermediate, Posterior and Panuveitis

Below you will find ICD-10 codes for non-infectious intermediate and panuveitis, as well as multiple subtypes of posterior uveitis. The codes included in this chart are not intended to encourage or suggest a use of any drug that is inconsistent with FDA-approved use. Please refer to the current policy for the latest codes since these codes are subject to change.

Diagnosis	ICD-10
Intermediate Uveitis	
Posterior cyclitis	
Right eye	H30.21
Left eye	H30.22
Bilateral	H30.23
Unspecified eye	H30.20
Panuveitis	
Panuveitis	
Right eye	H44.111
Left eye	H44.112
Bilateral	H44.113
Unspecified eye	H44.119
Posterior Uveitis	
Exudative retinopathy	
Right eye	H35.021
Left eye	H35.022
Bilateral	H35.023
Unspecified eye	H35.029
Retinal vasculitis	
Right eye	H35.061
Left eye	H35.062
Bilateral	H35.063
Unspecified eye	H35.069

Diagnosis	ICD-10
Posterior Uveitis (continued)	
Unspecified focal chorioretinal inflammation (choroiditis/chorioretinitis - NOS)	
Right eye	H30.001
Left eye	H30.002
Bilateral	H30.003
Unspecified eye	H30.009
Focal chorioretinal inflammation, juxtapapillary	
Right eye	H30.011
Left eye	H30.012
Bilateral	H30.013
Unspecified eye	H30.019
Focal chorioretinal inflammation of posterior pole	
Right eye	H30.021
Left eye	H30.022
Bilateral	H30.023
Unspecified eye	H30.029
Focal chorioretinal inflammation, peripheral	
Right eye	H30.031
Left eye	H30.032
Bilateral	H30.033
Unspecified eye	H30.039

NOS = Not otherwise specified

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Ocular or Periocular Infections: YUTIQ is contraindicated in patients with active or suspected ocular or periocular infections including most viral disease of the cornea and conjunctiva including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections and fungal diseases.

Hypersensitivity: YUTIQ is contraindicated in patients with known hypersensitivity to any components of this product.

Please see additional Important Safety Information on reverse and full Prescribing Information in pocket.



Diagnosis	ICD-10
Posterior Uveitis (continued)	
Focal chorioretinal inflammation, macular or paramacular	
Right eye	H30.041
Left eye	H30.042
Bilateral	H30.043
Unspecified eye	H30.049
Unspecified disseminated chorioretinal inflammation (chorioretinitis/choroiditis)	
Right eye	H30.101
Left eye	H30.102
Bilateral	H30.103
Unspecified eye	H30.109
Disseminated chorioretinal inflammation (choroiditis/chorioretinitis) posterior pole	
Right eye	H30.111
Left eye	H30.112
Bilateral	H30.113
Unspecified eye	H30.119
Disseminated chorioretinal inflammation (chorioretinitis/choroiditis) peripheral	
Right eye	H30.121
Left eye	H30.122
Bilateral	H30.123
Unspecified eye	H30.129
Disseminated chorioretinal inflammation, generalized	
Right eye	H30.131
Left eye	H30.132
Bilateral	H30.133
Unspecified eye	H30.139

Diagnosis	ICD-10
Posterior Uveitis (continued)	
Unspecified chorioretinal inflammation	
Unspecified chorioretinal inflammation, right eye	H30.91
Unspecified chorioretinal inflammation, left eye	H30.92
Unspecified chorioretinal inflammation, bilateral	H30.93
Unspecified chorioretinal inflammation, unspecified eye	H30.90
Other chorioretinal inflammations	
Other chorioretinal inflammations, right eye	H30.891
Other chorioretinal inflammations, left eye	H30.892
Other chorioretinal inflammations, bilateral	H30.893
Unspecified chorioretinal inflammation, unspecified eye	H30.899
Harada's disease	
Right eye	H30.811
Left eye	H30.812
Bilateral	H30.813
Unspecified eye	H30.819
Vogt-Koyanagi syndrome	
Right eye	H20.821
Left eye	H20.822
Bilateral	H20.823
Unspecified eye	H20.829

NOS = Not otherwise specified

IMPORTANT SAFETY INFORMATION (cont'd)

WARNINGS AND PRECAUTIONS

Intravitreal Injection-related Effects: Intravitreal injections, including those with YUTIQ, have been associated with endophthalmitis, eye inflammation, increased or decreased intraocular pressure, and choroidal or retinal detachments. Hypotony has been observed within 24 hours of injection and has resolved within 2 weeks. Patients should be monitored following the intravitreal injection.

Steroid-related Effects: Use of corticosteroids including YUTIQ may produce posterior subcapsular cataracts, increased intraocular pressure and glaucoma. Use of corticosteroids may enhance the establishment of secondary ocular infections due to bacteria, fungi, or viruses. Corticosteroids are not recommended to be used in patients with a history of ocular herpes simplex because of the potential for reactivation of the viral infection.

Risk of Implant Migration: Patients in whom the posterior capsule of the lens is absent or has a tear are at risk of implant migration into the anterior chamber.

ADVERSE REACTIONS

In controlled studies, the most common adverse reactions reported were cataract development and increases in intraocular pressure.

Please see full Prescribing Information in pocket.



©2019, EyePoint Pharmaceuticals, Inc. All rights reserved.
480 Pleasant Street, Suite B300, Watertown, MA 02472

YUTIQ and the EyePoint logo are trademarks of EyePoint Pharmaceuticals, Inc.

4/2019 US-YUT-1900038

